AstraZeneca Plc agreed to buy the Belgian biotech EsoBiotec for as much as $1 billion in a deal that will see the British ...

(Reuters) -Drugmaker AstraZeneca said on Monday it will buy biotechnology firm EsoBiotec for up to $1 billion. EsoBiotec's ...

The FTSE 100 index is set for a flat start to the session as attention turns to an important week for monetary policy ...

Acquisition includes EsoBiotec’s world-leading in vivo delivery platform with potential to transform cell therapyMONT-SAINT-GUIBERT, Belgium, March 17, 2025 (GLOBE NEWSWIRE) -- EsoBiotec SA, a ...

Promising therapies for platinum-resistant ovarian cancer produced mixed results in separate trials. The AKT inhibitor ...

The AstraZeneca PLC ADR AZN advanced 1.42% to $77.60 Friday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ Composite Index COMP rising 2.61% to ...

AstraZeneca has built its leading presence in the pharma and biotech industry on patent-protected drugs and a developing pipeline that support a wide moat. The strong replenishment of new drugs sets ...

Yu Jianlong, vice chairman of CCPIT, said British enterprises, including Rio Tinto, AstraZeneca, HSBC, Swire, BP, and British ...

Use of cystatin C for chronic kidney disease evaluation and sodium–glucose cotransporter-2 inhibitors as first-line therapy ...

In 2025, Cellectis will continue to focus its efforts and expenses on advancing its core clinical trials BALLI-01 and NATHALI ...

AstraZeneca is hopping aboard the pickleball craze as its serves up a new marketing push for its asthma med Fasenra. | ...

A cohort study of over 40,000 patients suggests that levels should be monitored for at least three months — longer than commonly practiced ...